Effect of preservation solution choice on antibody-mediated rejection after heart transplantation.
Verma
Divya Ratan
DR
Drakos
Stavros G
SG
Stehlik
Josef
J
Horne
Benjamin D
BD
Kfoury
Abdallah G
AG
D000328:Adult; D004187:Disaccharides / Q000627:therapeutic use; D004573:Electrolytes / Q000627:therapeutic use; D005260:Female; D005971:Glutamates / Q000627:therapeutic use; D005978:Glutathione / Q000627:therapeutic use; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control*; D006333:Heart Failure / Q000601:surgery*; D016027:Heart Transplantation / Q000276:immunology*; D006639:Histidine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008353:Mannitol / Q000627:therapeutic use; D008875:Middle Aged; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D019188:Organ Preservation Solutions / Q000627:therapeutic use*; D016896:Treatment Outcome
C088453:Celsior; D004187:Disaccharides; D004573:Electrolytes; D005971:Glutamates; D019188:Organ Preservation Solutions; D008353:Mannitol; D006639:Histidine; D005978:Glutathione